$15M upfront payment for a B-OM GLOBAL license ($1B-$2B market) is comical. Phase 3 for B-OM should require 200-300 patients, so the cost will be much lower than B-ABSSSI’s $30M (1400 patients). Therefore, BP paying for Phase 3 doesn’t mean that much. IPIX can pay for it when push comes to shove.
My expectation is at least $50M upfront for B-OM. Leo knows he needs $30M for B-ABSSSI and $20M for the year. We all know Theravance got $100M upfront for a Phase 1 IBD drug and Protaganist got $50M upfront for a pre-clinical IBD drug (both from J&J). B-OM is ready for Phase 3, possibly under Breakthrough Therapy Designation.
My expectation is at least $50M upfront for B-OM. Leo knows he needs $30M for B-ABSSSI and $20M for the year. We all know Theravance got $100M upfront for a Phase 1 IBD drug and Protaganist got $50M upfront for a pre-clinical IBD drug (both from J&J). B-OM is ready for Phase 3, possibly under Breakthrough Therapy Designation.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
